- $1.39bn
- $1.48bn
- $53.04m
U.S. STOCKS ON THE MOVE-Nike, Occidental Petroleum, Veeco Instruments
U.S. STOCKS ON THE MOVE-Nike, Occidental Petroleum, Carvana
AnaptysBio climbs after Leernik raises PT on investor-friendly spinoff plans
Brief: Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026
AnaptysBio Q2 collaboration revenue doubles
AnaptysBio Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. RESEARCH ROUNDUP-GE Vernova, NVR, ServiceNow
U.S. STOCKS ON THE MOVE-TransMedics, Centrus Energy, MongoDB
U.S. STOCKS ON THE MOVE-Boeing, GlobalFoundries, Tesla
AnaptysBio rises after H.C. Wainwright upgrades to 'buy' on arthritis drug progress
Brief: Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
AnaptysBio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: AnaptysBio Q1 Net Income USD -39.329 Million
Brief: AnaptysBio Q4 Net Income USD -21.784 Million
U.S. STOCKS ON THE MOVE-Chefs' Warehouse, Aptose Biosciences, Electromed
AnaptysBio climbs on arthritis drug trial data
Brief: Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial
Brief: Anaptys To Announce Top-Line Data From Phase 2B Trial Of Rosnilimab, A PD-1 Depleter And Agonist, In Rheumatoid Arthritis
Brief: Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab